Menu
when added to metformin vs metformin plus placebo (p<0.0001)
secondary benefit when added to metformin vs metformin plus placebo
5-10 mg dose taken at any time of day, regardless of meals
Remepan® offers additional benefits beyond HbA1c control, including increased weight loss and improvements to the cardiovascular and renal systems, decreasing morbidity and mortality for type 2 diabetes patients. Remepan® has demonstrated efficacy in lowering glucose and HbA1c levels in groups receiving Remepan® 5mg and Remepan® 10mg in combination with metformin. After receiving treatment with Remepan® for 24 weeks, both groups had lowered HbA1c levels to >48 mmol/ml (6.5%).
Patients treated with Remepan® experienced greater weight loss compared to placebo- and previous standard of care treatments, with a weight loss of 6lb in patients receiving Remepan® 5mg+meformin compared to 2.9lb in the control group. Due to the inclusion of SGLT2 inhibitors, patients receiving treatment with Remepan® are likely to reduce cardiovascular and renal complications, such as myocardial infarction, heart failure, urinary albumin creatine imbalance, and acute kidney failure, as well as slowing the progression of chronic kidney disease.
Patients are likely to experience a better management of type 2 diabetes symptoms, as well as a meaningful improvement in cardiovascular health and an improvement quality of life as diabetes type 2 symptoms are reduced.
Remepan® is beneficial to improve glycemic control in adults with type 2 diabetes.
Many patients prefer oral treatments over injectables, improving overall adherence to treatment to diabetes type 2 medications such as Remepan® 5mg and Remepan® 10mg.